Shares of Savara Inc (NASDAQ:SVRA) have received an average rating of “Hold” from the nine brokerages that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $8.60.
SVRA has been the subject of several recent analyst reports. LADENBURG THALM/SH SH reiterated a “hold” rating and issued a $1.00 price objective on shares of Savara in a report on Thursday, October 3rd. Evercore ISI set a $17.00 price objective on shares of Savara and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Zacks Investment Research upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Friday, November 8th.
Shares of NASDAQ:SVRA traded down $0.11 during trading hours on Wednesday, hitting $1.20. The stock had a trading volume of 434,152 shares, compared to its average volume of 409,860. The stock’s fifty day simple moving average is $0.94 and its 200 day simple moving average is $3.14. Savara has a 1-year low of $0.69 and a 1-year high of $11.96. The firm has a market capitalization of $49.45 million, a price-to-earnings ratio of -0.93 and a beta of 0.27. The company has a debt-to-equity ratio of 0.23, a quick ratio of 13.07 and a current ratio of 13.07.
Institutional investors have recently bought and sold shares of the company. Sullivan Bruyette Speros & Blaney LLC bought a new position in shares of Savara in the second quarter valued at approximately $38,000. DekaBank Deutsche Girozentrale boosted its holdings in shares of Savara by 67.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 20,600 shares of the company’s stock valued at $50,000 after acquiring an additional 8,300 shares in the last quarter. Parametric Portfolio Associates LLC bought a new position in shares of Savara in the second quarter valued at approximately $59,000. United Capital Financial Advisers LLC bought a new position in shares of Savara in the second quarter valued at approximately $61,000. Finally, Metropolitan Life Insurance Co NY bought a new stake in Savara during the first quarter worth approximately $83,000. Institutional investors and hedge funds own 40.42% of the company’s stock.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Recommended Story: The Structure of a Futures Contract
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.